MapLight Posts $51.6M Q3 Loss, $463.4M Cash Through 2028
MPLT sits 22% above its 52-week low of $6.06.
Summary
MapLight reported a $51.6 million Q3 loss and $463.4 million in cash, enough to fund operations through 2028. It also disclosed a timeline discrepancy on ZEPHYR-2 topline (2H 2027 in the headline vs 2028 in the body) and is pausing preclinical spending.
Key Events · Earnings and Guidance · MPLT
-
Q3 Loss Widens to $51.6M
Net loss was $51.6 million ($0.97 per share) vs $29.4 million ($37.18 per share) in Q3 2025; R&D rose to $44.2 million and G&A to $11.1 million.
-
Cash Runway Through 2028
Cash, cash equivalents and investments totaled $463.4 million as of September 30, 2026, expected to fund operations through 2028.
-
ZEPHYR-2 Timeline Conflict
The release headline says ZEPHYR-2 topline in 2H 2027, but the body says 2028; start-up activities have begun ahead of an FDA End-of-Phase 2 meeting.
-
Preclinical Spending Paused
MapLight is pausing significant further investment in preclinical and discovery-stage programs to focus resources on ML-007C-MA.
Analysis · MPLT · Life Sciences
The balance sheet is the story here: $463.4 million in cash funds operations through 2028, past the ZEPHYR-2 and VISTA readouts, even as the Q3 loss of $51.6 million ($0.97/share) widened from a year ago. The filing also flags a timeline inconsistency — the headline says ZEPHYR-2 topline in 2H 2027 while the body says 2028 — and confirms the company is pulling back from preclinical/discovery spending to concentrate on ML-007C-MA. For a clinical-stage biotech, cash runway and trial timing are what move the stock.
How filings like this one have moved
In the 30 days to Nov 15, 2026, 37.5% of the 3713 measured filings Wiseek scored 7 moved their stock by 5% or more by the next session's close. The median move was 0.00%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, MPLT was trading at $7.37 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $402.9M. The 52-week trading range was $6.06 to $40.43. This filing was assessed with neutral market sentiment and an importance score of 7 out of 10.